Cargando…

13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA

BACKGROUND: Cognition is a major determinant of functioning in patients with schizophrenia. There is evidence that the endocannabinoid system influences cognition in human subjects, and participates in the pathophysiology of schizophrenia. In a previous study, we have shown that the expression of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Salgado, Joao, Ferretjans, Rodrigo, Panizzutti, Bruna, Rosa, Eduarda, Gama, Clarissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887465/
http://dx.doi.org/10.1093/schbul/sby014.052
_version_ 1783312309228142592
author Salgado, Joao
Ferretjans, Rodrigo
Panizzutti, Bruna
Rosa, Eduarda
Gama, Clarissa
author_facet Salgado, Joao
Ferretjans, Rodrigo
Panizzutti, Bruna
Rosa, Eduarda
Gama, Clarissa
author_sort Salgado, Joao
collection PubMed
description BACKGROUND: Cognition is a major determinant of functioning in patients with schizophrenia. There is evidence that the endocannabinoid system influences cognition in human subjects, and participates in the pathophysiology of schizophrenia. In a previous study, we have shown that the expression of cannabinoid receptors (CB1R and CB2R) on peripheral lymphocytes is inversely correlated with performance in the Brief Assessment of Cognition in Schizophrenia (BACS), in patients with schizophrenia. Recently, CBRs polymorphisms have been associated with an increased risk for schizophrenia, structural changes in the central nervous systems and in cognitive performance of the patients. The aim of the present study was to investigate the association between CBRs polymorphisms and cognitive performance as assessed by the BACS. METHODS: A sample of 85 stable medicated patients (61% men; age = 41.6 ± 12.2 years; illness duration = 12.8 ± 10.7 years) was enrolled in this study. Two CB1R polymorphisms (rs1049353; rs12720071) and one CB2R polymorphism (rs2229579) were tested. RESULTS: We did not find any difference in general cognitive performance (BACS total score) regarding the three polymorphisms tested. However, when we analysed specific cognitive domains we have found a significant difference (p=0.002) regarding working memory (assessed by the Digit Span test) in patients with the rs12720071 polymorphism, where those with allele C performed better than those with T/T genotype. Since about a third of the patients (34%) had a history of past use of cannabis and 2.5% reported current use, we performed the rs12720071 polymorphism analysis excluding these patients. In this subgroup of patients, those with allele C also performed significantly better on Digit Span test (p=0.037). DISCUSSION: In this sample, the rs12720071 polymorphism of CB1R appears to influence performance on a working memory task that is sensitive to prefrontal cortex function.
format Online
Article
Text
id pubmed-5887465
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58874652018-04-11 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA Salgado, Joao Ferretjans, Rodrigo Panizzutti, Bruna Rosa, Eduarda Gama, Clarissa Schizophr Bull Abstracts BACKGROUND: Cognition is a major determinant of functioning in patients with schizophrenia. There is evidence that the endocannabinoid system influences cognition in human subjects, and participates in the pathophysiology of schizophrenia. In a previous study, we have shown that the expression of cannabinoid receptors (CB1R and CB2R) on peripheral lymphocytes is inversely correlated with performance in the Brief Assessment of Cognition in Schizophrenia (BACS), in patients with schizophrenia. Recently, CBRs polymorphisms have been associated with an increased risk for schizophrenia, structural changes in the central nervous systems and in cognitive performance of the patients. The aim of the present study was to investigate the association between CBRs polymorphisms and cognitive performance as assessed by the BACS. METHODS: A sample of 85 stable medicated patients (61% men; age = 41.6 ± 12.2 years; illness duration = 12.8 ± 10.7 years) was enrolled in this study. Two CB1R polymorphisms (rs1049353; rs12720071) and one CB2R polymorphism (rs2229579) were tested. RESULTS: We did not find any difference in general cognitive performance (BACS total score) regarding the three polymorphisms tested. However, when we analysed specific cognitive domains we have found a significant difference (p=0.002) regarding working memory (assessed by the Digit Span test) in patients with the rs12720071 polymorphism, where those with allele C performed better than those with T/T genotype. Since about a third of the patients (34%) had a history of past use of cannabis and 2.5% reported current use, we performed the rs12720071 polymorphism analysis excluding these patients. In this subgroup of patients, those with allele C also performed significantly better on Digit Span test (p=0.037). DISCUSSION: In this sample, the rs12720071 polymorphism of CB1R appears to influence performance on a working memory task that is sensitive to prefrontal cortex function. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5887465/ http://dx.doi.org/10.1093/schbul/sby014.052 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Salgado, Joao
Ferretjans, Rodrigo
Panizzutti, Bruna
Rosa, Eduarda
Gama, Clarissa
13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title_full 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title_fullStr 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title_full_unstemmed 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title_short 13.4 CANNABINOID RECEPTOR GENE POLYMORPHISMS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA
title_sort 13.4 cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887465/
http://dx.doi.org/10.1093/schbul/sby014.052
work_keys_str_mv AT salgadojoao 134cannabinoidreceptorgenepolymorphismsandcognitiveperformanceinpatientswithschizophrenia
AT ferretjansrodrigo 134cannabinoidreceptorgenepolymorphismsandcognitiveperformanceinpatientswithschizophrenia
AT panizzuttibruna 134cannabinoidreceptorgenepolymorphismsandcognitiveperformanceinpatientswithschizophrenia
AT rosaeduarda 134cannabinoidreceptorgenepolymorphismsandcognitiveperformanceinpatientswithschizophrenia
AT gamaclarissa 134cannabinoidreceptorgenepolymorphismsandcognitiveperformanceinpatientswithschizophrenia